Page 4 - David Lebwohl News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Intellia Therapeutics, Inc (NASDAQ:NTLA) Receives $75 47 Consensus Target Price from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average rating of “Moderate Buy” from the eighteen research firms that are presently covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and fifteen have assigned a buy recommendation to the company. The average twelve-month […]

Raymond jamesJohnm leonardDavid lebwohlSecurities exchange commissionGoldman sachs groupIntellia therapeutics company profileIntellia therapeutics incBlue trust incPenserra capital managementMorgan stanleyChina universal asset management coGroup wealth managementIntellia therapeuticsGet free reportExchange commissionInvestment management

31,266 Shares in Intellia Therapeutics, Inc (NASDAQ:NTLA) Acquired by Resonant Capital Advisors LLC

31,266 Shares in Intellia Therapeutics, Inc (NASDAQ:NTLA) Acquired by Resonant Capital Advisors LLC
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Nova scotiaUnited statesRaymond jamesDavid lebwohlJohnm leonardResonant capital advisorsSecurities exchange commissionMorgan stanleyBlackrock incRoyal bankGoldman sachs groupIntellia therapeutics incNorges bankExchange commissionAmerica corpIntellia therapeutics

FY2025 Earnings Estimate for Intellia Therapeutics, Inc Issued By Brookline Capital Management (NASDAQ:NTLA)

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) – Equities researchers at Brookline Capital Management raised their FY2025 earnings per share estimates for shares of Intellia Therapeutics in a research report issued on Sunday, January 7th. Brookline Capital Management analyst L. Cann now forecasts that the company will post earnings of ($5.12) per share for the […]

Raymond jamesDavid lebwohlJohnm leonardGoldman sachs groupMorgan stanleyBlair william coIntellia therapeutics company profileMetlife investment managementIntellia therapeutics incCibc world market incIntellia therapeuticsFree reportBrookline capital managementCapital managementIntellia therapeuticGet free report

JPM24, Day 3: Gene editors take the stage to talk BD

JPM24, Day 3: Gene editors take the stage to talk BD
fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.

Erick luceraSam kulkarniDavid lebwohlVertex pharmaceuticalsHealthcare conferenceTherapeutics chief medical officer david lebwohlBig pharmasEditas medicineChief financial officer erick luceraEdita cas

Intellia Therapeutics Gets Phase III Greenlight from FDA for Gene Editing Therapy

The trial, which is the first late-stage study of an in vivo CRISPR treatment in the U.S., will start by the end of 2023. Intellia's NTLA-2001 is a treatment candidate for transthyretin amyloidosis cardiomyopathy.

David lebwohlJohn leonardIntellia therapeuticNtellia gets phase iii greenlight from fda for gene editing therapy